Document is current

Article History

Received: 12 October 2022

Accepted: 3 December 2022

First Online: 21 December 2022

Declarations

:

: The study protocol and informed consent were approved by the Ethics Committees of the Champalimaud Foundation, Portugal (24^th May 2022) and of the Hospital General Universitario Gregorio Marañón Hospital, Spain (22^nd May 2022). Written informed consent is required and will be obtained prior to participation in this study.

: Not applicable.

: MM: Research grants from Roche, PUMA and Novartis, consulting/advisory fees from AstraZeneca, Amgen, Taiho Oncology, Roche/Genentech, Novartis, PharmaMar, Eli Lilly, PUMA, Taiho Oncology, Daiichi Sankyo and Pfizer and speakers’ honoraria from AstraZeneca, Lilly, Amgen, Roche/Genentech, Novartis, and Pfizer.SL-T: Consultant/Advisory Role: Celgene, Novartis, Pierre Fabre, Pfizer, Roche, Astra-Zeneca, Daiichi Sankyo, MSD, Seagen, Gilead and Lilly; Speaking: Novartis, Roche, Lilly.TM: Consulting or Advisory Boards: AstraZeneca, Novartis, Roche, GSK. Travel Grants: Novartis, Astra Zeneca.AJO-M was national coordinator for Portugal of a non-interventional study (EDMS-ERI-143085581, 4.0) to characterize a Treatment-Resistant Depression Cohort in Europe, sponsored by Janssen-Cilag, Ltd (2019–2020), is recipient of a grant from Schuhfried GmBH for norming and validation of cognitive tests, and is national coordinator for Portugal of trials of psilocybin therapy for treatment-resistant depression, sponsored by Compass Pathways, Ltd (EudraCT number 2017–003288-36), and of esketamine for treatment-resistant depression, sponsored by Janssen-Cilag, Ltd (EudraCT NUMBER: 2019–002992-33).The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.